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Non-alcoholic fatty liver disease, 
vascular inflammation and insulin 
resistance are exacerbated by 
TRAIL deletion in mice
Siân P. Cartland  1,2, Hanis H. Harith3,4, Scott W. Genner1, Lei Dang3, Victoria C. Cogger5,6, 
Melissa Vellozzi1, Belinda A. Di Bartolo1, Shane R. Thomas3, Leon A. Adams7 & Mary M. 
Kavurma1,2
Non-alcoholic fatty liver disease (NAFLD) incorporates steatosis, non-alcoholic steato-hepatitis (NASH) 
and liver cirrhosis, associating with diabetes and cardiovascular disease (CVD). TNF-related apoptosis-
inducing ligand (TRAIL) is protective of CVD. We aimed to determine whether TRAIL protects against 
insulin resistance, NAFLD and vascular injury. Twelve-week high fat diet (HFD)-fed Trail−/− mice had 
increased plasma cholesterol, insulin and glucose compared to wildtype. Insulin tolerance was impaired 
with TRAIL-deletion, with reduced p-Akt, GLUT4 expression and glucose uptake in skeletal muscle. 
Hepatic triglyceride content, inflammation and fibrosis were increased with TRAIL-deletion, with 
elevated expression of genes regulating lipogenesis and gluconeogenesis. Moreover, Trail−/− mice 
exhibited reduced aortic vasorelaxation, impaired insulin signaling, and >20-fold increased mRNA 
expression for IL-1β, IL-6, and TNF-α. In vitro, palmitate treatment of hepatocytes increased lipid 
accumulation, inflammation and fibrosis, with TRAIL mRNA significantly reduced. TRAIL administration 
inhibited palmitate-induced hepatocyte lipid uptake. Finally, patients with NASH had significantly 
reduced plasma TRAIL compared to control, simple steatosis or obese individuals. These findings 
suggest that TRAIL protects against insulin resistance, NAFLD and vascular inflammation. Increasing 
TRAIL levels may be an attractive therapeutic strategy, to reduce features of diabetes, as well as liver 
and vascular injury, so commonly observed in individuals with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition in the Western world and an 
increasingly common indication for liver transplantation1, 2. It incorporates a spectrum of liver diseases char-
acterized by abnormal accumulation of lipid (steatosis) arising in the absence of excess alcohol consumption. 
These diseases cover a continuum of stages ranging from steatosis, to nonalcoholic steatohepatitis (NASH) and 
cirrhosis, eventually resulting in liver failure. NAFLD is strongly associated with type-2 diabetes (T2D), with 
NASH patients displaying hepatic insulin resistance, inflammation and fibrosis3. NAFLD is not only associated 
with metabolic syndrome but is also an independent risk factor for cardiovascular disease (CVD), with CVD 
accounting for majority of deaths in patients with this disease3. Understanding the molecular and cellular hepatic 
changes that occur with progressive NAFLD will lead to the development of more sophisticated treatment options 
for these people.
Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a membrane bound and soluble 
cytokine found throughout the body. Originally identified because of its high sequence homology to TNF-α 
and Fas ligand (FasL), TRAIL can promote apoptosis and non-apoptotic pathways4–7, however, its role in vivo 
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in normal physiology is unclear. TRAIL is implicated in the pathogenesis of CVD and diabetes with circulat-
ing levels reduced in people with disease8, 9. Importantly, TRAIL-deletion in Apoe−/− mice leads to increased 
plasma cholesterol and glucose, accelerating atherosclerosis and features of diet-induced diabetes10; risk factors 
for NAFLD. The extent to which TRAIL protects against NAFLD is unclear. In this study, we examined (i) levels of 
circulating TRAIL in patients with increasing NAFLD severity; (ii) NAFLD pathogenesis using murine models of 
TRAIL-deletion; and (iii) the direct effect of TRAIL in NAFLD in vitro. Here we show that TRAIL protects against 
NASH, and may be a promising therapeutic for the treatment of NAFLD and associated pathologies.
Results
Patients with NASH have reduced circulating TRAIL strongly associating with plasma 
ALT. Clinical data are summarized in Table 1. Patients with NASH had significantly increased body mass 
index (BMI), waist circumference and were diabetic, compared to individuals with simple steatosis. NASH 
patients also had significantly elevated plasma alanine transaminase (ALT), aspartate aminotransferase (AST) 
and triglycerides, with reduced high-density-lipoprotein (HDL)-cholesterol. Histologically, increased steatosis, 
inflammation, ballooning and fibrosis were observed with NASH; and consistent with the histological diagnosis 
of NASH, the NAFLD activity score (NAS) was >5 in these individuals. Importantly, circulating TRAIL levels 
were significantly reduced in patients with NASH compared to controls, but not simple steatosis (Fig. 1a). There 
was no change in circulating TRAIL between control and obese individuals (Fig. 1b). Further, we examined the 
correlation between plasma TRAIL levels and multiple metabolic, clinical and biochemical parameters including 
age, BMI, serum glucose, insulin, triglyceride, HDL-cholesterol and AST levels (Supplemental Table 1), and found 
no associations with TRAIL and these metabolic, clinical or biochemical variables. However, a strong negative 
correlation between plasma TRAIL and ALT was observed in NASH patients (Fig. 1c). Serum ALT remained 
significantly associated with plasma TRAIL levels after adjustment for diabetes using linear regression analysis 
(beta −0.504, p = 0.004). The relationship remained robust and significant following further adjustment for BMI, 
age and sex (beta −0.461, p = 0.01). These findings indicate that with liver injury, independently of diabetes, cir-
culating TRAIL levels are reduced and inversely associate with plasma ALT.
NAFLD reduces circulating TRAIL and alters TRAIL receptor expression in vitro and in vivo. To 
directly delineate the effect of free fatty acids on hepatocytes and TRAIL expression, we used an in vitro model 
of NAFLD11. As expected, treatment of HepG2 cells with BSA-conjugated palmitate significantly increased oil 
red O staining, which is indicative of triglyceride content (Fig. 2a). This increase in triglyceride-content was also 
associated with increased expression of inflammatory and fibrotic markers (Fig. 2b,c). In contrast, lipid loading 
significantly reduced (~50%) TRAIL mRNA expression (Fig. 2d), while DR4 and DR5 expression was elevated, 
with only DR4 reaching significance (Fig. 2e,f). Importantly, exogenous TRAIL treatment of hepatocytes signifi-
cantly reduced palmitate-induced lipid uptake in vitro by ~30% (Fig. 2g).
Wildtype mice fed a HFD for 12 w develop NAFLD12. In response to a HFD, wildtype mice exhibited sig-
nificant increases in body weight, fasting plasma glucose, insulin and total cholesterol (Supplemental Table 2). 









(n = 10) P value
Age (years) 48.9 (8.7) 40.0 (9.5) 39.1 (12.1) 52.0 (14.9) 0.11
Male (n, %) 4 (44%) 0 (0%) 4 (40%) 4 (40%) 0.009
BMI (kg/m2) 24.6 (2.7) 38.9 (6.0) 36.2 (8.6) 34.1 (4.6) 0.001
Waist Circumference (cm) 82 (8) 107 (19) 99 (39) 118 (15) 0.02
Diabetes (n, %) 0 (0%) 0 (0%) 1 (10%) 7 (70%) 0.001
ALT (IU/l) 26 (8) 32 (8) 55 (29) 159 (163)* 0.003
AST (IU/l) 27 (7) 18 (4) 23 (14) 86 (95)* 0.01
Glucose (mmol/l) 5.0 (0.5) 4.9 (0.4) 4.4 (3.3) 7.9 (5.2) 0.07
Insulin (U/l) 3.8 (1.3) 14.1 (9.3) 12.1 (14.1) 31.4 (49.7)* 0.15
Triglyceride (mmol/l) 0.9 (0.3) 1.0 (0.3) 1.5 (1.2) 3.0 (1.5)* 0.001
HDL-Cholesterol (mmol/l) 1.6 (0.2) 1.4 (0.4) 1.3 (0.4) 0.9 (0.1)* <0.001
Total Cholesterol (mmol/l) 4.9 (0.8) 5.4 (1.1) 4.7 (1.7) 4.5 (1.3) 0.56
Steatosis — 0 1.7 (0.7) 2.5 (0.5) 0.01
Inflammation — 0 0.0 (0.0) 1.3 (0.5) <0.001
Ballooning — 0 0.0 (0.0) 1.6 (0.5) <0.001
NAS — 0 1.7 (0.7) 5.4 (0.8) <0.001
Fibrosis — 0 0.0 (0.0) 2.1 (0.9) <0.001
Table 1. Clinical and biochemical characteristics of control, simple steatosis and NASH patients. Footnote: 
Continuous data presented as mean (standard deviation). Comparison between groups performed using 
Chi-squared test, or ANOVA with comparison between Simple Steatosis and NASH groups with Bonferroni 
correction, apart from histological parameters, which are compared using Mann-Whitney U test. *p < 0.05 for 
post-hoc comparison between simple steatosis and NASH patients.
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hepatocytes in vitro, a significant increase in hepatic TRAIL expression was observed in 0 vs. 12 w HFD wild-
type mice (Supplemental Fig. 1b), which associated with a significant reduction in hepatic mDR5 mRNA 
(Supplemental Fig. 1c). Similarly, TRAIL levels were increased in white adipose tissue (WAT), with mDR5 expres-
sion also increased (Supplemental Fig. 1d,e). These data demonstrate that changes to TRAIL signals in hepato-
cytes in vitro, do not reflect the changes observed in the complex setting of a fatty liver of wildtype mice in vivo.
Trail−/− mice display altered plasma chemistries. To assess whether TRAIL deletion alone affects met-
abolic changes, 12 w HFD wildtype were compared with 12 w HFD Trail−/− mice. In contrast to our previous 
findings in Trail−/−Apoe−/− vs. Apoe−/− mice10, there was no observed difference in body weight (Supplemental 
Table 2), food intake or total energy expenditure (Supplemental Table 3) between wildtype and Trail−/− mice. 12 
w HFD Trail−/− mice did however, display an increase in rearing activity compared to wildtype (Supplemental 
Table 3). Importantly, Trail−/− had elevated plasma glucose, insulin and cholesterol levels, with a significant reduc-
tion in plasma triglycerides when compared to 12 w HFD wildtype mice (Supplemental Table 3). Collectively 
these findings indicate that HFD-fed Trail−/− mice have a more profound T2D phenotype.
Figure 1. Patients with NASH have reduced circulating TRAIL. (a) Circulating TRAIL levels in control, 
steatosis or NASH patients. (b) Circulating TRAIL levels in control and obese individuals. (c) Correlation 
between plasma TRAIL and ALT levels (Spearman rho −0.516, p = 0.003). Natural log (ln) of serum ALT 
presented graphically. n = 9–10/group; ANOVA and Mann Whitney U test.
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Trail−/− mice have impaired insulin sensitivity. 12 w HFD Trail−/− mice did not respond to an insulin chal-
lenge, such that their plasma glucose levels remained markedly higher over 2 h (Fig. 3a). TRAIL-deletion at baseline 
(0 w HFD) also resulted in reduced sensitivity to insulin at 60 min following an insulin bolus (Fig. 3b). No change in 
glucose tolerance was observed (Fig. 3c,d). Skeletal muscle from 12 w HFD Trail−/− mice had impaired insulin-induced 
p-Akt (Fig. 3e), as well as reduced glucose transporter-4 (GLUT4) expression (Fig. 3f) and glucose uptake ex vivo at 
baseline (Fig. 3g). Insulin resistance in skeletal muscle of 12 w HFD Trail−/− mice was associated with significantly 
increased expression of TNF-α (Fig. 3h). No change in monocyte chemo-attractant protein-1 (MCP-1), interleukin-1β 
(IL-1β), interleukin-6 (IL-6) and TNF-α expression was observed in muscle tissue at baseline (Fig. 3i). Importantly, adi-
pose tissue did not compensate for the skeletal muscle effects, since insulin-inducible glucose uptake was also impaired 
in WAT ex vivo (Supplemental Fig. 2). These findings suggest that the presence of TRAIL improves insulin sensitivity, 
and that TRAIL-gene deletion impairs insulin signaling and promotes insulin resistance.
Trail−/− mice have altered glucose and lipid metabolism. Given that TRAIL-deletion promoted 
a T2D phenotype, we next wanted to examine whether hepatic glucose and lipid metabolism was altered in 
these mice. While glucose uptake in liver was significantly impaired with TRAIL-deletion at baseline (Fig. 4a), 
no change in glucose-6-phosphatase or GLUT2 expression was observed (Fig. 4b). Baseline Trail−/− mice chal-
lenged with insulin showed significantly increased hepatic phosphoenolpyruvate carboxykinase (PEPCK) mRNA 
(Fig. 4c), and increased glycogen content (Fig. 4d). Furthermore, there was a significant increase in hepatic 
expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCoAR; Fig. 4f), with a trend for increased sterol 
regulatory element-binding protein-1 (SREBP1; Fig. 4e) expression. These data imply that the presence of TRAIL 
improves hepatic glucose and lipid metabolism.
Liver from Trail−/− exhibit altered liver pathology in response to a HFD. We next examined liver 
of 12 w HFD Trail−/− vs. wildtype mice for evidence of NAFLD pathology. Fat engorged hepatocytes were clearly 
seen in both genotypes (Fig. 5a). Importantly, oil red O staining was significantly elevated with TRAIL deletion 
(Fig. 5b). 12 w HFD Trail−/− liver also displayed increased fibrosis and apoptosis (Fig. 5c,d), with no change in 
mDR5 expression (Fig. 5e). Hepatic stellate cell activation plays a key role in the development of fibrosis13; these 
Figure 2. TRAIL protects against lipid uptake in HepG2 cells. (a) Palmitate increases triglyceride uptake in 
HepG2 cells over 5 days as measured by Oil red O. (b) Inflammation and (c) fibrotic markers are increased in 
HepG2 cells in response to palmitate over 5 d. (d) mRNA expression for TRAIL is significantly reduced with 
lipid uptake over time. (e) DR4 and (f) DR5 expression in response to palmitate. (g) 1 ng/ml TRAIL inhibits 
palmitate-induced oil red O in HepG2 cells at 24 h compared to the vehicle PBS. Control, untreated cells; 
n = 3–4/treatment. mRNA expression was normalized to GAPDH. Results are expressed as mean ± SEM; 
ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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cells can be identified by vimentin staining in the quiescent state14, or smooth muscle α-actin (SMA) staining in 
the active state15. While vimentin expression was significantly reduced in 12 w HFD Trail−/− liver (Fig. 5f), SMA 
was significantly elevated (Fig. 5g), reflecting a de-differentiation of the cells to a fibroblastic state15. Thus, global 
TRAIL gene deletion in mice exacerbates NAFLD/NASH in response to a HFD.
Dietary cholesterol is essential for TRAIL-dependent NAFLD/NASH. It has been proposed that 
increased dietary cholesterol is critical in the development of NAFLD/NASH in humans16 and in experimental 
models17. As the HFD employed in this study contains 0.15% cholesterol, we next assessed whether added cho-
lesterol in the diet is critical for TRAIL-dependent NAFLD/NASH. For this we placed wildtype and Trail−/− mice 
on a lard diet for 12 w; containing a similar fat content to the HFD, without cholesterol. While 12 w lard Trail−/− 
mice had significantly increased plasma glucose levels compared to wildtype, no changes in body weight, plasma 
cholesterol, triglycerides, insulin or NEFA were observed (Supplemental Table 4). No change in GTT or ITT was 
also evident (Supplemental Fig. 3a,b). Importantly, there was no change in hepatic triglyceride content in these 
mice (Supplemental Fig. 3c). Collectively, these suggest that dietary cholesterol is essential for the development 
and severity of NAFLD with TRAIL-deletion.
Trail−/− vascular tissue is insulin resistant and displays inflammation. NAFLD is strongly associ-
ated with T2D and vascular injury, with CVD an independent risk factor3. Insulin-induced aortic vasodilation was 
impaired with TRAIL deletion at baseline (Fig. 6a), and more profoundly at 12 w HFD (Fig. 6b). In contrast, ace-
tylcholine (Ach) or sodium nitroprusside (SNP)-induced vasodilation was unaltered (Fig. 6c). Importantly, insulin 
signaling was impaired, with aortic p-Akt expression in response to insulin, markedly reduced in 12 w HFD Trail−/− 
mice (Fig. 6d). 12 w HFD Trail−/− mice also had ~50–70% reduced insulin receptor and GLUT4 mRNA (Fig. 6e).
Figure 3. Trail−/− mice have impaired insulin sensitivity. (a) Insulin tolerance tests (ITT) in 12 w HFD mice 
(left panel); expressed as area under the curve (right panel; n = 10/genotype) or, (b) ITT at baseline (0 w HFD 
wildtype and Trail−/− mice; n = 3/genotype). (c) Glucose tolerance tests in 12 w HFD mice (left panel; n = 10/
genotype) or, (d) at baseline (0 w HFD wildtype and Trail−/− mice; n = 3/genotype). (e) Western blotting 
showing that muscle from insulin-stimulated 12 w HFD Trail−/− mice have reduced p-Akt protein expression 
(3 independent mice/group). Total Akt protein expression is unaltered. (f) GLUT4 staining in muscle from 
insulin-stimulated (45 min) 0 w HFD Trail−/− and wildtype mice (n = 4/genotype) and (g) reduced glucose 
uptake ex vivo (n = 3–4/genotype). (h) Inflammatory marker expression is increased in muscle tissue of 12 w 
HFD Trail−/− vs. wildtype, but not at (i) baseline (n = 4–5/genotype). mRNA expression was normalized to 
β-actin. Results are expressed as mean ± SEM; ANOVA or Mann Whitney U test. *p < 0.05 and **p < 0.01.
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The effect of a HFD on TRAIL expression in vascular tissues is not known and low-grade chronic inflamma-
tion is important in the development of vascular disease. In response to a HFD, wildtype mice had 2 to 5-fold 
increases in aortic expression of MCP-1, TNF-α, IL-1β, IL-6 and TRAIL (Fig. 7a). Compared to 12 w HFD wild-
type mice however, TRAIL-deletion resulted in marked elevation of aortic TNF-α (22-fold), IL-1β (20-fold) 
and IL-6 (31-fold) (Fig. 7b). Of note, only vascular MCP-1, IL-1β (Fig. 7c) and VCAM-1 (Fig. 7d) expression 
were significantly elevated with TRAIL-deletion at baseline. These findings suggest that Trail−/− vessels are insu-
lin resistant and have impaired downstream insulin signals. Moreover, Trail−/− vessels are more susceptible to 
inflammation, which is accelerated in response to a HFD.
Discussion
The key novel findings of this study are: first, that plasma TRAIL levels are significantly reduced in patients 
with the severe form of NAFLD (i.e. NASH), negatively associating with plasma ALT, even after adjustment for 
diabetes, BMI, age and sex. Second, in response to a HFD with cholesterol, mice with TRAIL-deletion develop 
a marked increase in hepatic steatosis, display altered hepatic cholesterol and glucose homeostasis, and many 
features of NASH. Mechanistically, free-fatty acid overload in hepatocytes was associated with reduced TRAIL 
mRNA, with TRAIL administration inhibiting lipid accumulation in vitro. Third, we show that Trail−/− mice are 
more susceptible to insulin resistance, inflammation, develop T2D and vascular injury in response to a HFD. 
This is the first report showing that TRAIL protects against hepatic steatosis, inflammation and fibrosis; features 
of NASH. These findings are significant because increased consumption of energy-dense food has resulted in a 
pandemic of NAFLD, diabetes and CVD affecting approximately 30% of the world’s population.
The clinical importance of TRAIL in people with NAFLD is uncertain, but does, on balance, favor a beneficial 
effect. One small study examined soluble TRAIL levels in NAFLD patients from China18. This study indicated that 
the C/G allele polymorphisms in the TRAIL gene at position 1525/1595 were higher in NAFLD than healthy indi-
viduals, associating with increased serum TRAIL18. On the other hand, the same group showed that the AATT 
genotype frequencies at 1525/1595 were lower with NAFLD, associating with reduced soluble TRAIL levels18. 
Notably, this report was unable to determine the association between TRAIL levels, NASH and simple steatosis. 
Figure 4. Liver from Trail−/− mice exhibit altered glucose and lipid metabolism. (a) Hepatic glucose uptake ex 
vivo is reduced in baseline 0 w HFD Trail−/− vs. wildtype mice (n = 3–5/genotype). mRNA expression for (b) 
Glucose-6 phosphatase (G6Pase) or GLUT2 mRNA in baseline mice. (c) Insulin-stimulated PEPCK mRNA 
expression is increased in baseline Trail−/− mice (n = 6/genotype). (d) 12 w HFD Trail−/− mice exhibit increased 
PAS staining and have (e) elevated SREBP-1 and (f) HMGCoAR mRNA expression (n = 6/genotype). mRNA 
expression was normalized to HPRT. Results are expressed as mean ± SEM; Mann-Whitney U-test; *p < 0.05, 
and ***p < 0.001.
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Here, we show that circulating TRAIL levels are significantly reduced in people with NASH but not with obese 
individuals, and strongly correlate with levels of ALT.
Hepatic steatosis occurs when there is an imbalance in hepatic fatty acid and triglyceride acquisition and removal. 
The main sources of free fatty acids in the liver are (i) NEFA released from adipose stores; (ii) de novo lipogenesis 
(e.g. from glucose) involving transcriptional regulation by factors including SREBP-1; and (iii) free fatty acids from 
dietary intake. Surprisingly, and in contrast to our previous findings in 12 w HFD Trail−/−Apoe−/− mice10, no changes 
in food intake, body weight and adipose tissue weight (not shown) were observed between Trail−/− and wildtype 
mice. The surplus lipids observed in Trail−/−Apoe−/− (e.g. plasma cholesterol, triglycerides, LDL and VLDL10), may 
further promote an increase in adipocyte hypertrophy and body weight, not evident with TRAIL-deletion alone. 
Indeed, excessive lipid can stimulate adipocyte hypertrophy19, and promote adiposity in people20.
We found no change in plasma NEFA with TRAIL-deletion alone, nor between 12 w HFD Trail−/−Apoe−/− vs. 
Apoe−/− mice (not shown), suggesting that NEFA released from fat stores does not affect hepatic triglyceride 
levels in these mice. Increases in hepatic HMGCoAR (and to some extent SREBP-1) with TRAIL deletion, imply 
that cholesterol and triglyceride synthesis is increased in the liver. Moreover, TRAIL-deletion alone impaired 
the ability of the liver to remove triglyceride, since more was evident by oil red O staining in HFD Trail−/− mice. 
Importantly, these changes in Trail−/− mice were only evident in response to a HFD with cholesterol. Of note, die-
tary fat and cholesterol are known to synergistically interact, enhancing NASH and metabolic changes in mice by 
an ~2-fold greater extent, than achieved with a fat or cholesterol diet alone21; a finding also supported in humans 
with NASH16. Therefore, added dietary cholesterol in a HFD is essential for the NAFLD/NASH we observe with 
TRAIL-deletion in mice.
Figure 5. Liver from 12 w HFD Trail−/− mice have NAFLD. (a) Liver from 12 w HFD Trail−/− mice have 
elevated steatosis compared to 12 w HFD wildtype mice (40× magnification). (b) Oil red O is increased in 
hepatic tissue of 12 w HFD Trail−/− vs. wildtype. (c) Milligan’s trichrome quantification of fibrosis shows that 
12 w HFD Trail−/− mice have increased fibrosis. (d) Hepatic tissue from 12 w HFD Trail−/− mice have increased 
apoptosis, measured using the Cell Death Detection ELISA. (e) mDR5 expression is unaltered in 12 w HFD 
Trail−/− vs. wildtype liver. mRNA expression was normalized to β-actin. (f) Vimentin staining is increased 
in liver from 12 w HFD wildtype mice (arrows), while (g) SMA staining is increased in 12 w HFD Trail−/− 
liver (arrows). Staining was quantified as described in the Materials and Methods. Results are expressed as 
mean ± SEM (n = 10/genotype); Mann-Whitney U-test; *p < 0.05.
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In humans, TRAIL signaling occurs upon binding and trimerization of its death receptors, DR4 and DR5. 
In mice, there is only one TRAIL death receptor, mDR5 with ~60% homology to both DR4 and DR5. Both 
TRAIL and DR5 are expressed in human hepatocytes in vitro22. TRAIL itself can induce apoptosis of normal 
human hepatocytes at high, non-physiological, concentrations23; with free-fatty acids sensitizing human hepat-
ocytes to TRAIL-mediated apoptosis via DR524. Mice fed a fibrogenic methionine and choline-deficient diet 
develop NAFLD, with an increase in hepatic mDR5 expression and apoptosis25, suggesting that mDR5 signals 
promote a NAFLD phenotype. Furthermore, Dr5−/− mice fed a high fat, high sucrose and high cholesterol diet 
for 3 months, not dissimilar to our HFD, had reduced hepatic steatosis, inflammation and markers of fibrosis26. 
Fas has also been implicated in NAFLD in people27, and in experimental models28, 29. Reduced hepatic steatosis 
was also observed in mice with Fas deletion specifically from adipocytes30. These data imply that TNF ligands may 
promote NAFLD pathogenesis via their cognate receptors. However, the direct effect of TRAIL in experimental 
models of NAFLD is unknown. We found that global TRAIL-gene deletion in mice promoted a more severe 
NAFLD phenotype with increased lipid accumulation, inflammation and fibrosis. This apparently contradictory 
finding may be explained by ligand-independent receptor activation. While no changes in mDR5 mRNA between 
genotype in the liver was observed, Trail−/− hepatic tissues had significantly increased apoptosis. Intriguingly, an 
overload of lipid in hepatocytes promotes DR5 localization into lipid rafts, stimulating cell death independent 
of TRAIL binding31 and further, ligand independent hepatocyte apoptosis has also been observed for Fas32, 33. 
Whether TRAIL or ligand-independent mechanisms promote liver injury in this setting is unclear and requires 
further elucidation.
We also found Trail−/− mice were insulin resistant, with TRAIL deletion impairing insulin signaling and glu-
cose homeostasis. PEPCK is an enzyme that controls the rate of glucose synthesis with the ability to modulate 
plasma glucose levels34. Overexpression of PEPCK promotes T2D34. The increase in plasma glucose levels and 
glycogen content in Trail−/− mice may reflect the role PEPCK plays in regulating hepatic glucose (and cholesterol) 
homeostasis. Collectively, our study implies that TRAIL improves insulin sensitivity by modulating expression 
of genes involved in glucose metabolism and insulin signaling. Consistent with this, plasma TRAIL levels in 
T2D patients after gastric banding surgery were increased and correlated with improved β-cell function35. TNF 
Figure 6. Trail−/− vascular tissue have altered insulin signals. Concentration-response curves for ex vivo aortic 
relaxation induced by insulin at (a) baseline 0 w HFD or (b) 12 w HFD wildtype and Trail−/− mice; (n = 5/
genotype). (c) Concentration-response curves for ex vivo aortic relaxation induced by Ach (left) and SNP (right) 
in 12 w HFD mice. (d) Aortas from 12 w HFD Trail−/− mice in response to an insulin challenge (45 min) have 
reduced p-Akt protein expression, with no change in total Akt levels. (e) Aortic mRNA expression of insulin 
receptor-β and GLUT-4 in 12 w HFD Trail−/− vs. wildtype; mRNA levels were normalised to β-actin (n = 3/
genotype). Results are expressed as mean ± SEM; ANOVA or Mann-Whitney U-test; *p < 0.05, **p < 0.01, 
***p < 0.001.
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ligand regulation of insulin signaling and glucose homeostasis may in fact be a common theme in diabetics, since 
TNF-α and FasL have also been implicated in insulin resistance36, 37.
Insulin resistance can also develop in cardiovascular tissues where insulin can contribute to the development 
of CVD, hypertension and metabolic diseases38. In wildtype mice, we observed a significant reduction in circulat-
ing TRAIL levels in response to a HFD, correlating with an elevation of vascular expression of IL-1β, MCP-1, IL-6 
and TNF-α, pro-inflammatory cytokines known to play key roles in insulin resistance and diabetes39. In contrast 
to circulating TRAIL levels, vascular TRAIL expression (including in liver and fat) was significantly increased in 
these mice. Discrepancies between circulating vs. tissue TRAIL expression have been observed in other inflam-
matory diseases. For example, plasma TRAIL levels are reduced in patients with chronic kidney disease40, and 
increased TRAIL in kidneys is associated with disease severity in diabetic nephropathy41. While this suggests that 
TRAIL may play an inflammatory role and promote disease, importantly, our global TRAIL knockout studies in 
nephropathy42 and here, demonstrate the opposite. In fact, compared to HFD-fed wildtype mice, TRAIL-deletion 
resulted in >20-fold elevation of inflammatory marker mRNA in the vessel wall. Increased expression of inflam-
matory markers was also observed in the liver and in fat (not shown). Thus, Trail−/− mice are more susceptible to 
inflammation, suggesting that early inflammatory events occur with TRAIL deletion alone. Our findings are of 
major importance. Rather than promoting inflammation and disease, the presence of TRAIL may in fact exert an 
overall anti-inflammatory action in damaged or injured tissues, resulting in protection against injury.
This study has revealed a critical role of TRAIL in blunting metabolic diseases. Our findings show for the 
first time that deletion of TRAIL causes systemic insulin resistance, increases hepatic cholesterol and glucose 
production and renders the liver more susceptible to triglyceride accumulation and injury, promoting a more 
severe form of NAFLD in response to a HFD. Importantly, these metabolic changes are associated with increased 
dysfunction and inflammation in blood vessels. Taken together, we speculate that these findings may translate 
into a therapeutic use for TRAIL as a novel anti-inflammatory agent with vascular protective actions. Indeed, the 
therapeutic potential of TRAIL in reducing HFD-induced inflammation, adiposity and improving glucose sensi-
tivity in mice has previously been reported43. It is therefore possible that in the future, TRAIL and related agents, 
may offer new therapeutic options for patients with NAFLD, diabetes and CVD.
Materials and Methods
Human studies. Adults with biopsy-proven NAFLD, obese individuals with normal liver biopsies or healthy 
controls were recruited. Informed consent was obtained from all subjects. All methods were carried out in 
accordance with guidelines and regulations from the National Health and Medical Research Council of Australia; 
Figure 7. Trail−/− mice display severe vascular tissue inflammation in response to a HFD. (a) Aortic mRNA 
expression for MCP-1, TNF-α, IL-6, IL-1β and TRAIL in 0 vs. 12 w HFD wildtype mice (n = 4–5/treatment). (b) 
Aortic mRNA expression for inflammatory markers in 12 w HFD or (c) baseline Trail−/− vs. wildtype mice. (d) 
Baseline Trail−/− have increased aortic mRNA for VCAM-1 but not ICAM-1. mRNA levels were normalized to 
β-actin or 18S and expressed as mean ± SEM; Mann-Whitney U-test (n = 4–5/genotype); *p < 0.05.
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experimental protocols were approved by the Sir Charles Gairdner Hospital Human Research Ethics Committee 
(2007–098). Healthy controls were defined by the presence of normal liver enzymes and absence of medical con-
ditions requiring medications. Plasma samples were taken following an overnight fast on the day of liver biopsy 
for patients with NAFLD, or on the day of clinical assessment for healthy controls and frozen at −80 °C. Plasma 
chemistries were assessed as previously described44. Biopsy specimens in NAFLD patients were staged by a liver 
histopathologist as NASH or non-NASH45.
Animal studies. Male Trail−/−10 and wildtype mice at 6 w of age, weighing 18–20 g were euthanized for base-
line studies, and or randomly grouped and placed on a ‘Western’ high fat diet (HFD; SF00–219; 22% Fat, 0.15% 
Cholesterol Semi-Pure Rodent Diet) or the Lard diet (SF04–001; 23.5% Fat Semi-Pure Rodent Diet) for 12 w; 
both from Specialty Feeds, Glen Forest, Western Australia. After an overnight fast, mice were anaesthetized by i.p. 
injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), or isoflurane (2%) via nose cone prior to euthanasia 
by cardiac exsanguination. Blood was collected and plasma stored at −80 °C. Gastrocnemius muscle, epididymal 
WAT, liver, and aorta were collected, fixed in formaldehyde for immunohistochemistry (IHC) or snap-frozen for 
gene and protein expression. All methods involving animals were carried out in accordance with guidelines and 
regulations from the National Health and Medical Research Council of Australia; experimental protocols were 
approved under the Animal Care and Ethics Committees at the University of New South Wales (11/71B) or the 
Sydney Local Health District (2013/049), Sydney Australia.
Metabolic cages. The Comprehensive Laboratory Animal Monitoring System (Columbus Instruments, 
Columbus, OH) was used at 12 w HFD. Oxygen consumption (VO2) and CO2 production (VCO2) were normal-
ized to body weight. The respiratory exchange ratio was calculated (VCO2/VO2). Ambulatory activity was exam-
ined where horizontal (XAMB) and vertical (ZTOT) movement were determined. Food intake was measured. All 
measurements were taken over 24 h.
Plasma analysis. Plasma glucose was measured using a glucometer (Accu-check Performa, Roche, 
Mannheim, Germany). Insulin (Mercodia, Uppsala, Sweden), cholesterol, triglycerides, NEFA (all from Wako 
Diagnostics, Richmond, VA, USA) and TRAIL (human, R&D Systems; murine, USCN Life Science Inc., Houston, 
USA) were assessed.
Glucose and insulin tolerance tests. Glucose and insulin tolerance tests (GTT, ITT) were performed as 
previously described42; ITTs were performed in non-fasted mice.
Myography. Mouse thoracic aortas were isolated, prepared and mounted on the multiwire myography sys-
tem (Danish Myo Technology, Denmark)46. Changes in isometric tension of aortic rings in response to insulin 
(1–100 ng/ml), acetylcholine (Ach; 0.3–3 μM) or sodium nitroprusside (SNP; 0.3 nM–1 μM) were measured and 
recorded using PowerLab data acquisition system (AD instruments).
Ex vivo glucose uptake studies. Soleus muscle, epididymal WAT and liver were isolated from 6 w old 
mice. Tissues were exposed to recombinant human insulin (100 nM) or vehicle (water) for 15 min, followed by 
1 mM 2-deoxyglucose (2DG) for 20 min. 2DG uptake was measured47.
Histology and IHC. Liver sections (3–5 μm) were stained with Milligan’s Trichrome for fibrosis and periodic 
acid-Schiff (PAS) for glycogen. For assessment of stellate cells, liver were stained for vimentin (1:500, Abcam, 
Cambridge, UK) and smooth muscle α-actin (SMA; 1:200, Novocastra, Melbourne Australia)48. Gastrocnemius 
muscle isolated from 0 w HFD mice challenged with insulin (1 U/kg, 45 min) were stained for GLUT4 (1:500, 
Abcam, Cambridge, UK). All control sections with primary antibody omitted were negative. Images were cap-
tured using an Olympus BX53 or Zeiss Axio Imager Z2 microscope. % of positive staining/tissue image area was 
quantified using Image-Pro Premier (Cybernetics, Bethesda, MD, USA)10.
Quantification of lipids from frozen liver tissue. Triglyceride accumulation from frozen liver was 
quantified as described49.
Tissue Culture. HepG2 cells obtained from ATCC were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% (v/v) fetal bovine serum, penicillin (5 U/mL), streptomycin (5 μg/mL) (Lonza) and 200 
mM L-glutamine (Lonza) in a humidified atmosphere of 5% CO2 at 37 °C. Cells were treated with bovine serum 
albumin-conjugated palmitate (Seahorse Bioscience, Massachusetts USA) to mimic NAFLD in vitro11.
RNA extraction, cDNA synthesis and qPCR. RNA was extracted from homogenized tissue using the 
All-Prep DNA/RNA/protein mini kit (Qiagen, Valencia, CA), or TRI reagent (Sigma) for cells. cDNA synthesis 
and real-time qPCR were performed as described10, 50, 51. Relative mRNA expression was normalized to house-
keeping genes HPRT, β-actin,18S or GAPDH52. Primer sequences are shown in Supplemental Table 5.
Protein extraction and Western blotting. Protein was extracted from homogenized tissue using the 
All-Prep DNA/RNA/protein mini kit, or by RIPA buffer. Proteins were resolved on 4–20% gradient gels (Bio-Rad, 
Sydney, Australia) and transferred onto Immobilon-P PVDF membrane (Millipore, Billerica, MA). Membranes 
were blocked with 5% skim milk or bovine serum albumin, followed by incubation with primary antibodies; 
β-actin (15 min, 1:30000, Sigma); insulin receptor-β (overnight, 1:2000, Santa Cruz Biotechnology); Akt1/2/3 
(overnight, 1:2000, Cell Signaling) and phosphorylated Akt1/2/3 (p-Akt, overnight, 1:1000, Cell Signaling). 
Horseradish peroxidase-conjugated secondary antibodies (Dako) were used and signal detected by chemilumi-
nescence (ECLTM, Western blotting detection reagent, GE Healthcare, Chalfont St Giles, Buckinghamshire, UK).
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Statistics. Results are expressed as mean ± SEM, unless stated otherwise, and analyzed using GraphPad Prism 
Version 6.0 (GraphPad Software, San Diego, CA, USA) or SSPS (IBM, version 21.0). Statistical comparisons were 
assessed with Student t-test, Mann Whitney U-test, or ANOVA (one- or two-way) with Bonferroni adjustment for 
multiple comparisons. Chi-squared test was also used where indicated. Bivariate correlation was assessed between 
human serum TRAIL and clinical and biochemical factors using Pearson or Spearman correlation coefficients, 
according to the distribution of data, with adjustment of p values using Bonferroni correction for multiple testing. 
The relationship between plasma TRAIL and ALT levels was further evaluated using multivariate linear regression 
analysis with adjustment for possible confounders. A value of p < 0.05 was considered significant.
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